Librela 5 mg (Bedinvetmab SOLUTION) 5 MG

LIBRELA 5 MG is a subcutaneous solution containing bedinvimab, used for managing specific conditions in veterinary medicine. This medication is designed to provide targeted relief and support for certain health issues in animals.

Strength

5 MG

Manufacturer / TM Owner

ZOETIS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

LIBRELA 5 MG is primarily used for managing pain and inflammation in animals. This solution is administered subcutaneously and is often prescribed by veterinarians to address conditions that require targeted relief. The active ingredient, bedinvimab, works to alleviate discomfort and improve quality of life for the animal.

Side Effects

Common effects of LIBRELA 5 MG may include localized reactions at the injection site, such as redness or swelling. Some animals may also experience temporary discomfort or changes in behavior. These effects are generally mild and should subside as the body adjusts to the medication.

Precautions & Warnings

LIBRELA 5 MG should be handled with care and stored as directed to maintain its effectiveness. It is important to follow the veterinarian's instructions for administration and to monitor the animal for any adverse reactions. Always ensure the solution is clear and free from particles before use.

Avoid Interactions

LIBRELA 5 MG may interact with other medications, so it is important to inform your veterinarian about any other treatments your animal is receiving. Certain substances, including other pain relievers or anti-inflammatory drugs, could potentially affect the efficacy or safety of LIBRELA 5 MG.

Frequently Asked Questions

LIBRELA 5 MG is used for managing pain and inflammation in animals, often prescribed by veterinarians for targeted relief.

LIBRELA 5 MG is administered subcutaneously, meaning it is injected under the skin. Follow your veterinarian's instructions for proper administration.

Common side effects may include localized reactions at the injection site, such as redness or swelling, and temporary discomfort.

It is important to consult your veterinarian before using LIBRELA 5 MG with other medications to avoid potential interactions.

LIBRELA 5 MG should be stored as directed by the manufacturer, typically in a cool, dry place away from direct sunlight.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.